John M. Kelly

This study uses cardiac transcriptomics in mice to compare immune responses during acute and chronic Trypanosoma cruzi infection, identifying shared and divergent features.

The paper shows that a combination of GNF6702 and benznidazole can cure experimental chronic Chagas disease with shorter treatment duration and fewer side effects.

The paper analyzes the transcriptome and proteome of quiescent T. cruzi epimastigotes to understand persistence mechanisms and improve drug development.

This study determines the 3D structures of TcPOP in open and closed conformations using cryo-EM and evaluates its immunogenicity through antibody responses in mice.

This study maps DNA G-quadruplexes in Trypanosoma brucei, showing enrichment in coding regions and functional impact of G4-stabilizing ligands on gene expression.

This study examines MCM protein expression and localization in Trypanosoma cruzi during metacyclogenesis and G1 arrest, revealing their role in cell cycle regulation and replication arrest.

This study shows that intermittent posaconazole treatment does not prevent cardiac and digestive tract pathologies in a chronic Chagas disease mouse model, even with high parasite burden reduction.

This study shows statins do not reduce parasite burden in a mouse model of Trypanosoma cruzi infection, suggesting clinical trials for trypanocidal activity are unjustified.

This study establishes a hamster model of Trypanosoma cruzi infection using bioluminescence imaging, revealing chronic tissue pathology and motor dysfunction not seen in mice.

The paper describes a panel of bioluminescent and fluorescent Trypanosoma cruzi strains to study Chagas disease, enabling real-time monitoring of infection dynamics and drug screening.

This study identifies benznidazole-treated Trypanosoma cruzi persisters as transient non-proliferative parasites, not localized to specific tissues, and suggests their survival may involve DNA damage response or pre-existing non-replicative states.